{
  "PMID": "32921663",
  "OWN": "NLM",
  "STAT": "MEDLINE",
  "DCOM": "20201013",
  "LR": "20201013",
  "IS": "1349-3299 (Electronic) 1349-2365 (Linking)",
  "VI": "61",
  "IP": "5",
  "DP": "2020 Sep 29",
  "TI": "Ivabradine-Induced Torsade de Pointes in Patients with Heart Failure Reduced Ejection Fraction.",
  "PG": "1044-1048",
  "LID": "10.1536/ihj.20-073 [doi]",
  "AB": "Ivabradine is a selective inhibitor of the sinoatrial node \"funny\" current, prolonging the slow diastolic depolarization. As it has the ability to block the heart rate selectively, it is more effective at a faster heart rate. It is recommended for the treatment of heart failure reduced ejection fraction in the presence of beta-blocker therapy for the further reduction of the heart rate. However, previous reports have shown the association of Torsade de pointes (TdP) with concurrent use of ivabradine and drugs resulting in QT prolongation or blockage of the metabolic breakdown of ivabradine. In this article, we report two cases of patients with heart failure reduced ejection fraction who developed TdP after ivabradine use. Our report highlights the need to exercise caution with the administration of ivabradine in the presence of a reduced repolarization reserve, such as QT prolongation or metabolic insufficiency.",
  "FAU": [
    "Jang, Ji-Hun",
    "Kwon, Sung Woo",
    "Lee, Man-Jong",
    "Ko, Kyu-Yong",
    "Park, Jin-Hee",
    "Yoon, Gwang-Seok",
    "Choi, Seong-Huan",
    "Beak, Yong-Soo",
    "Park, Sang-Don",
    "Shin, Sung-Hee",
    "Woo, Seong-Ill",
    "Kim, Dae-Hyeok",
    "Kwan, Jun"
  ],
  "AU": [
    "Jang JH",
    "Kwon SW",
    "Lee MJ",
    "Ko KY",
    "Park JH",
    "Yoon GS",
    "Choi SH",
    "Beak YS",
    "Park SD",
    "Shin SH",
    "Woo SI",
    "Kim DH",
    "Kwan J"
  ],
  "AD": [
    "Department of Hospital Medicine, Inha University College of Medicine.",
    "Department of Cardiology, Inha University Hospital Cardiovascular Center.",
    "Department of Cardiology, Inha University Hospital Cardiovascular Center.",
    "Department of Cardiology, Inha University Hospital Cardiovascular Center.",
    "Division of Critical Care Medicine, Inha University College of Medicine.",
    "Department of Cardiology, Inha University Hospital Cardiovascular Center.",
    "Department of Cardiology, Inha University Hospital Cardiovascular Center.",
    "Department of Cardiology, Inha University Hospital Cardiovascular Center.",
    "Department of Cardiology, Inha University Hospital Cardiovascular Center.",
    "Department of Cardiology, Inha University Hospital Cardiovascular Center.",
    "Department of Cardiology, Inha University Hospital Cardiovascular Center.",
    "Department of Cardiology, Inha University Hospital Cardiovascular Center.",
    "Department of Cardiology, Inha University Hospital Cardiovascular Center.",
    "Department of Cardiology, Inha University Hospital Cardiovascular Center.",
    "Department of Cardiology, Inha University Hospital Cardiovascular Center."
  ],
  "LA": [
    "eng"
  ],
  "PT": [
    "Case Reports",
    "Journal Article"
  ],
  "DEP": "20200912",
  "PL": "Japan",
  "TA": "Int Heart J",
  "JT": "International heart journal",
  "JID": "101244240",
  "RN": [
    "0 (Adrenergic beta-Antagonists)",
    "0 (Cardiovascular Agents)",
    "0 (Sodium Potassium Chloride Symporter Inhibitors)",
    "3H48L0LPZQ (Ivabradine)"
  ],
  "SB": "IM",
  "MH": [
    "Adrenergic beta-Antagonists/adverse effects",
    "Cardiovascular Agents/*adverse effects",
    "Drug Interactions",
    "Electric Countershock",
    "Electrocardiography",
    "Heart Failure/*drug therapy",
    "Humans",
    "Ivabradine/*adverse effects",
    "Male",
    "Middle Aged",
    "Sodium Potassium Chloride Symporter Inhibitors/adverse effects",
    "Stroke Volume",
    "Torsades de Pointes/*chemically induced"
  ],
  "OTO": [
    "NOTNLM"
  ],
  "OT": [
    "Polymorphic ventricular tachycardia",
    "QT prolongation"
  ],
  "EDAT": "2020/09/15 06:00",
  "MHDA": "2020/10/21 06:00",
  "CRDT": [
    "2020/09/14 05:47"
  ],
  "PHST": [
    "2020/09/15 06:00 [pubmed]",
    "2020/10/21 06:00 [medline]",
    "2020/09/14 05:47 [entrez]"
  ],
  "AID": [
    "10.1536/ihj.20-073 [doi]"
  ],
  "PST": "ppublish",
  "SO": "Int Heart J. 2020 Sep 29;61(5):1044-1048. doi: 10.1536/ihj.20-073. Epub 2020 Sep 12.",
  "abstract": "Ivabradine is a selective inhibitor of the sinoatrial node \"funny\" current, prolonging the slow diastolic depolarization. As it has the ability to block the heart rate selectively, it is more effective at a faster heart rate. It is recommended for the treatment of heart failure reduced ejection fraction in the presence of beta-blocker therapy for the further reduction of the heart rate. However, previous reports have shown the association of Torsade de pointes (TdP) with concurrent use of ivabradine and drugs resulting in QT prolongation or blockage of the metabolic breakdown of ivabradine. In this article, we report two cases of patients with heart failure reduced ejection fraction who developed TdP after ivabradine use. Our report highlights the need to exercise caution with the administration of ivabradine in the presence of a reduced repolarization reserve, such as QT prolongation or metabolic insufficiency.",
  "pmid": "32921663",
  "year": "2020",
  "title": "Ivabradine-Induced Torsade de Pointes in Patients with Heart Failure Reduced Ejection Fraction.",
  "source": "pubmed",
  "full_text": "1. Int Heart J. 2020 Sep 29;61(5):1044-1048. doi: 10.1536/ihj.20-073. Epub 2020\nSep  12.\n\nIvabradine-Induced Torsade de Pointes in Patients with Heart Failure Reduced \nEjection Fraction.\n\nJang JH(1)(2), Kwon SW(2), Lee MJ(2)(3), Ko KY(2), Park JH(2), Yoon GS(2), Choi \nSH(2), Beak YS(2), Park SD(2), Shin SH(2), Woo SI(2), Kim DH(2), Kwan J(2).\n\nAuthor information:\n(1)Department of Hospital Medicine, Inha University College of Medicine.\n(2)Department of Cardiology, Inha University Hospital Cardiovascular Center.\n(3)Division of Critical Care Medicine, Inha University College of Medicine.\n\nIvabradine is a selective inhibitor of the sinoatrial node \"funny\" current, \nprolonging the slow diastolic depolarization. As it has the ability to block the \nheart rate selectively, it is more effective at a faster heart rate. It is \nrecommended for the treatment of heart failure reduced ejection fraction in the \npresence of beta-blocker therapy for the further reduction of the heart rate. \nHowever, previous reports have shown the association of Torsade de pointes (TdP) \nwith concurrent use of ivabradine and drugs resulting in QT prolongation or \nblockage of the metabolic breakdown of ivabradine. In this article, we report \ntwo cases of patients with heart failure reduced ejection fraction who developed \nTdP after ivabradine use. Our report highlights the need to exercise caution \nwith the administration of ivabradine in the presence of a reduced \nrepolarization reserve, such as QT prolongation or metabolic insufficiency.\n\nDOI: 10.1536/ihj.20-073\nPMID: 32921663 [Indexed for MEDLINE]",
  "full_text_source": "abstract"
}